Why Investors Are Cautious on Abbott Laboratories (ABT)

1 hour ago 1

Attiya Zainib

Tue, June 2, 2026 astatine 11:33 AM CDT 2 min read

The Mairs & Power, an concern firm, released the first-quarter 2026 capitalist missive for the “Mairs & Power Balanced Fund.” A transcript of the missive tin beryllium downloaded here. The money returned -1.77% successful the archetypal 4th of 2026, outperforming its benchmark composite scale diminution of -2.68% arsenic beardown banal enactment and vulnerability to Utilities and Industrials helped offset marketplace volatility triggered by the Iran struggle and rising vigor prices. The money said ostentation concerns resurfaced aft Middle East tensions pushed lipid prices higher, causing the Federal Reserve to follow a much cautious stance connected involvement rates. Despite the uncertain backdrop, the steadfast maintained a constructive semipermanent outlook, citing resilient firm earnings, improving small-cap trends, and charismatic opportunities successful reasonably valued sectors specified arsenic Utilities, Industrials, and Health Care. In addition, you tin cheque the Fund’s apical 5 holdings to find its champion picks for 2026.

In its first-quarter 2026 capitalist letter, Mairs & Power Balanced Fund highlighted stocks similar Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is simply a healthcare institution that develops aesculapian devices, diagnostics, nutrition products, and branded medicines. The one-month instrumentality of Abbott Laboratories (NYSE:ABT) was -1.03% portion its shares traded betwixt $81.97 and $139.06 implicit the past 52 weeks. On June 1, 2026, Abbott Laboratories (NYSE:ABT) banal closed astatine astir $87.78 per share, with a marketplace capitalization of astir $152.25 billion.

Mairs & Power Balanced Fund stated the pursuing regarding Abbott Laboratories (NYSE:ABT) in its Q1 2026 capitalist letter:

"Also, negatively impacting show during the 4th was the Fund’s vulnerability to Health Care. Abbott Laboratories (NYSE:ABT) impacted show arsenic guidance successful the nutrition concern flagged and maturation decelerated elsewhere."

Why Investors Are Cautious connected Abbott Laboratories (ABT)

Abbott Laboratories (NYSE:ABT) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 73 hedge money portfolios held Abbott Laboratories (NYSE:ABT) astatine the extremity of the 4th quarter, compared to 71 successful the erstwhile quarter. While we admit the hazard and imaginable of Abbott Laboratories (NYSE:ABT) arsenic an investment, our condemnation lies successful the content that immoderate AI stocks clasp greater committedness for delivering higher returns and doing truthful wrong a shorter clip frame. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article